PACLITAXEL | BRISTOL-MYERS | ||
100MG/VIAL | |||
Yes | Yes | ||
2034-Jul-12 | Expired | ||
None | None | ||
None | No | ||
ABRAXANE™ for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. |
1 | 0 | 1 |
Total Other Developers | 3 |
---|
Drugs with Suitability | No |
---|
100MG/VIAL | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
Yes | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|---|---|---|---|---|
****** | ******* ****** | ******* ******* *************** **., ***. (******* **** ****) | *********** | ** ******* ****, ******** & ************* *********** ****,, ***********, ******* ******, ***** (***) | *** |
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com